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Background: Anemia occurs frequently in HIV-infected patients and has been associated with an increased risk of
death in this population. For Hispanic subjects, information describing this blood disorder during HIV is scarce.
Therefore, the present study examined data from a cohort of HIV-positive Hispanics to determine the prevalence of
anemia, identify its associated factors, and evaluate its relationship with one-year mortality.
Methods: This study included 1,486 patients who enrolled between January, 2000 and December, 2010 in an
HIV-cohort in Bayamón, Puerto Rico. Data were collected through personal interviews and medical record abstractions.
To determine the factors independently associated with anemia, a multivariable logistic regression model was used.
Kaplan-Meier and Cox proportional hazards models were also performed to estimate survival time and to predict
death risk.
Results: The prevalence of anemia at enrollment was 41.5%. Factors independently associated with increased odds of
anemia were: unemployment (OR = 2.02; 95% CI 1.45-2.79), CD4 count <200 cells/μL (OR = 2.66; 95% CI 1.94-3.66), HIV viral
load ≥100,000 copies/mL (OR = 1.94; 95% CI 1.36-2.78), white blood cell count <4,000 cells/μL (OR = 2.42; 95% CI 1.78-3.28)
and having clinical AIDS (OR = 2.39; 95% CI 1.39-4.09). Overweight (OR = 0.43; 95% CI 0.32-0.59) and obese (OR = 0.44; 95%
CI 0.29-0.67) BMI’s were independently associated with reduced odds of anemia. Survival differed significantly by anemia
status (log-rank test: p < 0.001). One-year mortality estimates were: 30.8%, 23.3%, 8.4% and 2.5%, for patients with severe,
moderate, mild and no anemia, respectively. Having anemia at baseline was independently associated with an increased
one-year mortality risk (severe anemia: HR = 9.06; 95% CI: 4.16-19.72; moderate anemia: HR = 6.51; 95% CI: 3.25-13.06; mild
anemia: HR = 2.53; 95% CI: 1.35-4.74).
Conclusions: A high prevalence of anemia at enrollment was observed in this cohort of HIV-infected Hispanics.
Unemployment and several adverse prognostic features of HIV infection were independently associated with this
blood disorder. Anemia resulted to be the strongest predictor of one-year mortality, evidencing a dose–response
effect. Further investigations are needed to evaluate whether recovering from anemia is associated with longer
survival, and to identify the types of anemia affecting this particular group of HIV patients.
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The development of hematological disorders in HIV-
infected patients was described a few years after the
first cluster of AIDS cases was identified [1,2]. Usually
defined as low hemoglobin levels or low hematocrit,
anemia is the most common cytopenia seen in the
course of HIV infection [3]. The prevalence of anemia
in persons with HIV has been determined in many
studies [4-14], with values that range between 19% and
69% [9,10]. Besides its commonness in people having
HIV, there has been recognized a linkage between anemia
and decreased survival in this population [15-18]. In fact,
anemia has been associated with an increased risk of
death in HIV-infected patients, independently of many
indicators of poor prognosis, such as: low CD4 cell count,
high HIV viral load or the manifestation of AIDS-defining
conditions [4,7,12,19-21].
The mechanisms associated to anemia in the context
of HIV infection are broadly classified in relation to an
inefficient hematopoietic process, resulting from: malnu-
trition, co-infections, neoplasms, decreased erythropoi-
etin production and the use of antiretroviral medications
[3,15,22]. Additional mechanisms are related to an in-
creased red blood cell (RBC) lost or destruction pro-
duced by gastrointestinal or genitourinary bleeding, and
entrapment of RBC in the spleen [3,22]. There are also
elements of socio-demographic, immunological and clin-
ical nature that have been frequently associated to the
coexistence of anemia in the HIV-infected population.
Some of these factors include: female sex [5,9,10,19], in-
creasing age [7,8], high HIV viral load [6,8,20], low CD4
cell count [5-10,12-14,20], presenting opportunistic in-
fections (clinical AIDS) [5,6,20], low body mass index
(BMI) [7,10,14] and intravenous drug use [5]. Other
cytopenias, including leucopenia and thrombocytopenia,
have been also associated to anemia in HIV-positive
patients [19].
Although information describing anemia during HIV
is already published, limited data is available on the
prevalence and impact of this disorder in specific pa-
tient groups [16], as it is with the Hispanic popula-
tion. Hispanics have been disproportionately affected
by the HIV epidemic [23]. In 2010, they comprised
16% of the total population living in the United
States and its territories [24], but accounted for the
21% of the new HIV cases reported [25]. The present
study examined data from a cohort of HIV-infected
patients living in Puerto Rico, a commonwealth terri-
tory of the United States in which 99% of its inhabi-
tants are Hispanics [24]. The objectives of this study
were directed to: 1) determine the prevalence of anemia,
2) identify its associated factors and 3) evaluate the rela-
tionship between this hematological disorder and one-
year mortality.Methods
Setting and study population
This study included HIV-positive adults (21 years or
older) who received their HIV-associated health care in
the Universidad Central del Caribe academic health cen-
ter (UCC) in Bayamón, Puerto Rico, either at the Ramón
Ruiz-Arnau University Hospital or at the HIV ambulatory
clinics. All patients with documented HIV infection seen
in these facilities are invited to enroll in the Retrovirus
Research Center HIV-cohort. If the patient agrees to par-
ticipate, the aims and procedures of the study are ex-
plained and a consent form is read, discussed and upon
acceptance, it is signed by the participant. Then, face to
face interviews and blood sample collections are per-
formed. After this initial assessment subsequent visits are
scheduled every six months. Patients considered for this
study had their enrollment between January, 2000 and
December, 2010. The study was approved by the UCC’s
Institutional Review Board.
Data collection and variables of interest
In this study we evaluated baseline information only.
The information collected at the first visit covered
the period within the date of interview and its pre-
ceding year. In addition to personal interviews, med-
ical record abstractions were used as data collection
methods. The laboratory results obtained from the
blood drawn during the day of visit were incorpo-
rated to the patients’ records before abstraction. For
patients in which multiple laboratory or clinical mea-
surements were available, only the most recent ones
were considered in the analysis.
The variables examined in this study were: age (≤35 years,
36–45 years, >45 years), sex (male, female), level of edu-
cation completed (less than high school, high school,
college), employment status (employed, unemployed),
lifetime alcohol use (yes, no), lifetime intravenous drug use
(yes, no), CD4 cell count (<200 cells/μL, ≥200 cells/μL),
HIV viral load (<10,000 copies/mL, 10,000-100,000 copies/
mL, >100,000 copies/mL), platelets count (<150,000 cells/
μL, ≥150,000 cells/μL), white blood cell count (<4,000
cells/μL, ≥4,000 cells/μL), clinical AIDS (yes, no) and anti-
retroviral treatment use (yes, no). BMI was estimated
using patients’ weight and height employing the fol-
lowing formula: weight (kg) / [height (m)]2. Patients’
BMI was further classified as underweight: <18.5 kg/m2,
normal: 18.5-24.9 kg/m2, overweight: 25.0-29.9 kg/m2
and obese: ≥30.0 kg/m2. Finally, anemia was defined as
hemoglobin levels < 12 g/dL in women and < 13 g/dL in
men, according to established guidelines [26].
For the survival analysis, as per a cooperative agree-
ment with the Puerto Rico Department of Health, mor-
tality information was obtained from their mortality
registry, up to December, 2011. Patients who did not have
Table 1 Description of study participants (n = 1,486)
Characteristic %
Males 67.3
Age, median (range) 40 (21–79)
Education level*







Intravenous drug use* 34.4
Clinical AIDS 9.5
CD4 count <200 cells/μL* 41.8
Received antiretroviral treatment 64.4
Anemia: Hb < 12 g/dL women, < 13 g/dL men 41.5
*Variable had missing values: Education level = 7; Employment status = 25;
Alcohol use = 7; Intravenous drug use = 2; CD4 count = 33.
Hb, hemoglobin level.
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considered as censored. In this analysis, anemia status was
sub-classified as: severe anemia (<8 g/dL), moderate
anemia (8–9.9 g/dL) and mild anemia (10–11.9 g/dL in
women and 10–12.9 g/dL in men).
Statistical analysis
Descriptive statistics were used to illustrate the charac-
teristics of the population under study and the overall
prevalence of anemia at enrollment. Prevalence of
anemia by socio-demographic, immunological and clin-
ical characteristics were also calculated and compared
through Chi-square tests. Variables with statistically sig-
nificant differences on that bivariate analysis were fur-
ther evaluated in a multivariable model to determine the
factors independently associated with anemia. Logistic
regression was employed and results were reported as
odds ratios (OR) with their respective 95% confidence
intervals (95% CI). Overall fit of the model was measured
with the Hosmer-Lemeshow goodness of fit test and
ascertained (p = 0.830).
Kaplan-Meier technique was also performed to esti-
mate one-year survival according to anemia status at en-
rollment. Differences in survival time were measured
with the log-rank test. Finally, a Cox proportional haz-
ards model was executed to assess the association be-
tween baseline anemia and risk of dying after one year,
controlling for possible confounders. Age, sex, BMI, CD4
cell count, HIV viral load, clinical AIDS and antiretroviral
treatment, all previously associated with mortality in
HIV-infected patients [4,7,20,21,27], were included in the
final model after an initial evaluation using univariable
analyses. Results were reported as hazard ratios (HR)
with corresponding 95% CI’s. The statistical software
Stata/SE (Version 12.1, College Station, TX, USA) was
used to carry out the analyses. All tests were two-sided
and significance was set at 0.05.
Results
Characteristics of the population studied and prevalence
of anemia
Between January, 2000 and December, 2010 a total of
1,502 patients were enrolled in the cohort. Of them, 16
patients did not have hemoglobin measurements at en-
rollment and were excluded of the study, for a total of
1,486 subjects. Median age of study participants was
40 years (range, 21–79), 67.3% were male, 68.6% had an
education level of at least high school and 25.0% were
employed. More than half of participants (51.5%) used
alcohol and 34.4% used intravenous drugs. A total of
41.8% had a CD4 cell count <200 cells/μL, 9.5% pre-
sented clinical AIDS and 64.4% received antiretroviral
medications. The overall prevalence of anemia at enroll-
ment was 41.5% (Table 1).Factors associated with anemia
The prevalence of anemia differed significantly (p < 0.05)
by: age, education level, employment status, BMI, CD4
cell count, HIV viral load, platelets count, white blood
cell count, clinical AIDS and antiretroviral treatment use
(Table 2). Anemia was more prevalent among older
(46.7% >45 years, 40.8% 36–45 years and 37.4% ≤35 years),
less educated (46.9% less than high school, 43.9% high
school and 32.0% college) and unemployed (46.6%,
25.5% employed) patients. The presence of anemia was
also more frequent among patients with: lower BMI
(74.4% underweight, 49.4% normal, 26.8% overweight
and 22.7% obese), lower CD4 cell count (63.2% <200
cells/μL, 23.9% ≥200 cells/μL), higher HIV viral load
(61.1% >100,000 copies/mL, 34.0% 10,000-100,000 copies/
mL and 25.4% <10,000 copies/mL), lower platelets count
(56.9% <150,000 cells/μL, 36.7% ≥ 150,000 cells/μL),
lower white blood cell count (66.9% <4,000 cells/μL,
29.4% ≥4,000 cells/μL), clinical AIDS (78.7%, 37.6% no
clinical AIDS) and antiretroviral medications received
(43.4%, 38.0% no ART).
When stratified by alcohol and intravenous drug use,
no significant differences were found in the prevalence
of anemia. Therefore, the association between anemia and
these variables were not considered beyond this point. All
other factors with significant differences in the prevalence
of anemia were included in the multivariable model. Sex
was not significantly associated to anemia in the bi-
variate analysis but considering findings from other studies
[5,9,10,19], it was also included in the final model.
Table 2 Relationship between socio-demographic, immunological and clinical characteristics of patients and anemia
Prevalence of anemia Univariable analysis Multivariable analysis*
Variable % p-value OR 95% CI OR 95% CI
Sex
Male 40.0 0.103 1 1
Female 44.4 1.20 0.96-1.49 1.30 0.98-1.74
Age (years)
≤35 37.4 0.016 1 1
36-45 40.8 1.15 0.90-1.48 0.96 0.70-1.32
>45 46.7 1.47 1.13-1.92 1.11 0.79-1.57
Education level
College 32.0 <0.001 1 1
High school 43.9 1.66 1.28-2.16 1.32 0.95-1.83
Less than high school 46.9 1.88 1.43-2.47 1.33 0.93-1.89
Employment status
Employed 25.5 <0.001 1 1
Unemployed 46.6 2.55 1.96-3.33 2.02 1.45-2.79
Alcohol use
No 39.5 0.148 1
Yes 43.2 1.17 0.95-1.43
Intravenous drug use
No 41.0 0.658 1
Yes 42.2 1.05 0.85-1.31
BMI (kg/m2)
Normal (18.5-24.9) 49.4 <0.001 1 1
Underweight (<18.5) 74.4 2.99 1.96-4.54 1.50 0.91-2.47
Overweight (25.0-29.9) 26.8 0.38 0.29-0.49 0.43 0.32-0.59
Obese (≥30.0) 22.7 0.30 0.21-0.43 0.44 0.29-0.67
CD4 count (cells/μL)
≥200 23.9 <0.001 1 1
<200 63.2 5.46 4.34-6.86 2.66 1.94-3.66
HIV viral load (copies/mL)
<10,000 25.4 <0.001 1 1
10,000-100,000 34.0 1.51 1.14-2.01 1.13 0.80-1.59
>100,000 61.1 4.62 3.53-6.03 1.94 1.36-2.78
Platelets count (cells/μL)
≥150,000 36.7 <0.001 1 1
<150,000 56.9 2.28 1.78-2.91 1.24 0.89-1.71
White blood cell count (cells/μL)
≥4,000 29.4 <0.001 1 1
<4,000 66.9 4.84 3.83-6.12 2.42 1.78-3.28
Clinical AIDS
No 37.6 <0.001 1 1
Yes 78.7 6.15 4.05-9.35 2.39 1.39-4.09
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Table 2 Relationship between socio-demographic, immunological and clinical characteristics of patients and anemia
(Continued)
Received ART
No 38.0 0.044 1 1
Yes 43.4 1.25 1.01-1.55 0.76 0.56-1.03
*Logistic regression, n = 1,307. Some patients (n = 179) were not considered in this analysis because they had missing values in any of the variables included in the model:
Education level = 7; Employment status = 25; Alcohol use = 7; Intravenous drug use = 2; BMI = 115; CD4 count = 33; HIV viral load = 27; Platelets count = 9.
BMI, body mass index; ART, antiretroviral treatment; OR, odds ratio; CI, confidence interval.
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model are also presented in Table 2. Unemployment
(OR = 2.02; 95% CI 1.45-2.79), CD4 count <200 cells/μL
(OR = 2.66; 95% CI 1.94-3.66), HIV viral load ≥100,000
copies/mL (OR = 1.94; 95% CI 1.36-2.78), white blood cell
count <4,000 cells/μL (OR = 2.42; 95% CI 1.78-3.28) and
having at least one AIDS- defining condition (OR = 2.39;
95% CI 1.39-4.09) were all significantly associated with
increased odds of anemia. On the contrary, overweight
(OR = 0.43; 95% CI 0.32-0.59) and obese (OR = 0.44; 95%
CI 0.29-0.67) BMI’s, compared to normal BMI, were sig-
nificantly associated with decreased odds of anemia. Sex,
age, education level, platelets count and antiretroviral
treatment were not associated with the presence of
anemia in this model.
Survival analysis
Based on the Kaplan-Meier method, survival at one year
differed significantly by anemia status at baseline (log-rank
test: p < 0.001, Figure 1). The proportion of patients to
have died after a year of follow-up was estimated in: 30.8%
for patients with severe anemia, 23.3% for patients with
moderate anemia, 8.4% for patients with mild anemia and
2.5% for patients without anemia. The Cox proportional
hazards model revealed that after controlling for age, sex,









Figure 1 Kaplan-Meier survival estimates according to anemia status
entry: severe anemia (<8.0 g/dL), moderate anemia (8.0-9.9 g/dL), mild ane
anemia (≥12.0 g/dL in women and ≥13.0 g/dL in men). Log-rank test wasantiretroviral treatment, having anemia at enrollment in-
creased significantly the one-year mortality risk of these
HIV-infected patients. Moreover, the strength of this asso-
ciation was related with the degree of anemia (severe
anemia: HR = 9.06; 95% CI: 4.16-19.72; moderate anemia:
HR = 6.51; 95% CI: 3.25-13.06; mild anemia: HR = 2.53; 95%
CI: 1.35-4.74). Other factors independently associated with
one-year mortality were: male sex (HR = 1.73; 95% CI: 1.06-
2.81), overweight BMI (HR = 0.34; 95% CI: 0.15-0.76) and
antiretroviral treatment use (HR = 0.51; 95% CI: 0.33-0.80)
(Table 3).
Discussion
The prevalence of anemia found in our cohort is within
the range observed in other studies targeting HIV-
infected patients [4-14]. However, when compared to
studies in which data on Hispanics was available, the
prevalence of anemia we obtained (41.5% overall; 44.4%
in women and 40.0% in men) was substantially higher.
For example, in the Anemia Prevalence Study, a large
multicenter study carried out in HIV-positive people in
the United States, the overall prevalence of anemia in
1,529 Hispanics was 31.3% (26.1% for women and 33.0%
for men) [8]. Similarly, the Women’s Interagency HIV
Study included 475 Hispanic patients, and reported an






at baseline. Anemia status based on hemoglobin levels at study
mia (10.0-11.9 g/dL in women and 10.0-12.9 g/dL in men) and no
used to compare survival estimates.






Variable HR 95% CI HR 95% CI
Sex
Female 1 1
Male 1.41 0.91-2.17 1.73 1.06-2.81
Age (years)
≤35 1 1
36-45 1.64 0.99-2.72 1.05 0.60-1.82
>45 1.91 1.14-3.23 1.41 0.80-2.48
BMI (kg/m2)
Normal (18.5-24.9) 1 1
Underweight (<18.5) 2.05 1.27-3.29 1.12 0.64-1.96
Overweight (25.0-29.9) 0.21 0.10-0.44 0.34 0.15-0.76
Obese (≥30.0) 0.41 0.20-0.86 0.91 0.42-2.00
CD4 count (cells/μL)
≥200 1 1
<200 3.35 2.18-5.15 1.20 0.68-2.09
HIV viral load (copies/mL)
<10,000 1 1
10,000-100,000 1.95 1.02-3.69 1.21 0.62-2.37
>100,000 4.04 2.29-7.10 1.55 0.81-2.98
Clinical AIDS
No 1 1
Yes 3.64 2.37-5.60 1.17 0.68-2.02
Received ART
No 1 1
Yes 0.65 0.45-0.95 0.51 0.33-0.80
Anemia: Hb (g/dL)
No (≥12.0 women, ≥13.0 men) 1 1
Mild (10.0-11.9 women,
10.0-12.9 men)
3.41 2.00-5.80 2.53 1.35-4.74
Moderate (8.0-9.9) 10.41 6.03-17.98 6.51 3.25-13.06
Severe (<8.0) 14.40 7.86-26.38 9.06 4.16-19.72
*Cox proportional hazards regression.
^n = 1,333. Excluded patients (n = 153) had missing values in any of the
variables included in the model: BMI = 115; CD4 count = 33; HIV viral load = 27.
BMI, body mass index; ART, antiretroviral treatment; Hb, hemoglobin level; HR,
hazard ratio; CI, confidence interval.
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the overall prevalence of anemia was 20.3% [13].
Many reasons may explain why our cohort has an
elevated prevalence of anemia. First of all, our study
included a high number of patients with advanced
immunological deterioration (41.8% of patients had a
CD4 cell count <200 cells/μL), which has been associated
to the development of anemia during HIV infection[17,22]. Also, our institution receives a large number of
care referrals from patients of low socioeconomic status,
as demonstrated by the 75.0% of patients who reported
being unemployed. This could lead to a sicker population
with delayed health seeking activities [28], and it is well
known that at a later stage of HIV disease the develop-
ment of comorbidities, such as anemia, is more common
[29]. We do not believe that the higher anemia preva-
lence in our population is related to a different standard in
defining anemia, since the definition we used is actually
more conservative than in other published works. All three
cited studies with Hispanic participants had the same
hemoglobin cutoff than us for women (<12 g/dL), but in
the Anemia Prevalence Study and Mata-Marín and col-
leagues’ study, a cut-point of <14 g/dL for men (1 g/dL
higher) was used. If employing this value in our study, the
prevalence of anemia in men would have been higher
at 57.9%, with an increased overall prevalence of anemia
of 53.5%.
Significant differences in the prevalence of anemia by
socio-demographic, clinical and immunological factors
were observed in this study. The finding that anemia is
more prevalent in older patients and those with lower
BMI, lower CD4 cell count, higher HIV viral load and
clinical AIDS has been previously documented [6,8,10,14].
When evaluating these and other factors in the multivari-
able model, unemployment, CD4 count <200 cells/μL,
HIV viral load >100,000 copies/mL, presence of clinical
AIDS and white blood cell count <4,000 cells/μL, were in-
dependently associated with augmented odds of anemia.
Conversely, overweight and obese BMI’s, were found to be
associated with reduced odds of anemia. With the excep-
tion of unemployment, all these factors have been associ-
ated to anemia in earlier studies [6-10,12,13,19,20].
To our knowledge, the relationship of unemployment
and anemia in HIV-infected patients has not been re-
ported before. Nonetheless, the design of this study does
not allow us to have a clear understanding of the finding.
Employment status is used as an indicator of socioeco-
nomic position, and has been shown that unemployed
people are less likely to receive an adequate medical care
[28]. HIV-infected patients under these conditions may
not be able to prevent the progression of HIV, which
could contribute to a deterioration of their health and
the occurrence of complications, such as anemia. On
the other hand, it can be argued that the presence of
fatigue and weakness associated to anemia, which affect
the quality of life and physical functioning of patients
[3,22,30], could also impede sustained employment. Thus,
future research efforts should be directed to evaluate this
association.
In agreement with several studies, we found a relation-
ship between lower levels of hemoglobin and higher
one-year mortality rates. A multicenter study conducted
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after a year of follow-up was 40.8% for patients with se-
vere anemia (<8 g/dL), 15.9% for patients with mild
anemia (8–12 g/dL in women and 8–14 g/dL in men)
and 3.1% for patients without anemia (>12 g/dL for
women and >14 g/dL for men) [4]. Likewise, in a study
of HIV-infected patients from Tanzania, the one-year
mortality estimates were: 55.2% in patients with severe
anemia (<8 g/dL), 37.6% in patients with moderate
anemia (8–9.9 g/dL), 20.0% in patients with mild anemia
(10–11.9 g/dL in women and 10–12.9 g/dL in men), and
3.7% in patients without anemia (≥12 g/dL for women
and ≥13 g/dL for men) [27].
The observation of anemia being a predictor of one-
year mortality in our cohort was confirmed when we an-
alyzed possible confounders in the proportional hazards
model. Other studies have also documented this inde-
pendent association [4,31]. In the EuroSIDA study, a
decrease in 1 g/dL of hemoglobin level augmented the
hazard of death (HR = 1.57; 95% CI: 1.41-1.75), after con-
trolling for demographic variables, antiretroviral treat-
ment, AIDS, CD4 count and viral load [4]. In addition,
Alemu and colleagues concluded that anemia was a pre-
dictor of mortality in a group of patients living in Ethiopia,
after adjusting for treatment, WHO clinical stage and body
weight [31].
In this study we found that anemia was the strongest
predictor of one-year mortality and that a higher degree
of anemia was related to a greater risk of dying. Simi-
larly, in a cohort of 2,348 HIV-positive patients from the
United States, severity grades of anemia were associated
with an increased mortality risk, after controlling for
CD4 cell count, age, antiretroviral treatment and devel-
opment of opportunistic infections [21]. Despite these
results, we consider the relationship between anemia
and one-year mortality in our population is not neces-
sarily causal. There are elements that could be mediating
in the mentioned association and were not included in
this study. For example, information regarding blood
transfusions, a common therapeutic practice for the
temporary correction of anemia, was not addressed.
Studies have associated this treatment with a worse prog-
nosis in HIV-infected patients, since it may have an
immunosuppressive effect on their already weakened im-
mune system [17,32]. Therefore, we believe that instead
of causing deaths directly, anemia might be an indicator
of a compendium of comorbid systemic states [20], which
ultimately contribute to these patients’ demise.
Our data provides additional evidence on the role of
anemia during HIV infection and also reveals its great
impact in this cohort of Hispanic subjects. Nevertheless,
limitations of this study should be mentioned. Firstly, as
variables were compiled at the same time, we were un-
able to establish that factors associated with anemiawere present before the disorder, and are either risk or
protective factors. In addition, all data we analyzed
(except mortality information) was obtained at the time
of study entry. Not evaluating clinical and laboratory in-
formation after baseline impeded us from having a more
precise scenario of the relationship between many vari-
ables that change over time (i.e., CD4 cell count, HIV
viral load, BMI, treatment, hemoglobin level) and survival.
Finally, as the sample for this study was conveniently
drawn, we cannot generalize our results to all HIV-infected
patients in Puerto Rico.
Conclusions
The presence of anemia at enrollment was relevant in this
cohort of HIV-infected Hispanics, and it was associated
with several adverse prognostic features of the HIV infec-
tion and unemployment. Most importantly, having anemia
at baseline was independently associated with an increased
mortality risk at one year. Future steps should focus on in-
tegrating the patients’ follow-up information to evaluate
whether recovering from anemia is associated with longer
survival, as has been described [19,21]. Further investiga-
tions are also needed to identify the types of anemia affect-
ing these patients, which would bring valuable information
on the causes of this abnormality, and will help to delineate
strategies in order to deal with this threatening comorbid-
ity in this particular group.
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